# US 2023/0271998 A1 · Solid support for synthesizing nucleic acid sequences and methods for making and using

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0271998 A1
- Document ID: US20230271998A1
- Status: Published application
- Kind: A1
- Application number: 18/003,404
- Filed: 2021-06-28
- Published: 2023-08-31
- Earliest claimed: 2020-06-30
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Inventors: Serge L. Beaucage; Andrzej M. Grajkowski
- Web page: https://patentgrep.com/patent/US20230271998A1

## CPC

- C07H 21/04: with deoxyribosyl as saccharide radical
- C07F 9/093: {Polyol derivatives esterified at least twice by phosphoric acid groups}
- C07F 9/098: {Esters of polyphosphoric acids or anhydrides}
- C07F 9/65515: {the oxygen atom being part of a five-membered ring}
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H 21/02: with ribosyl as saccharide radical
- C12N 15/1068: {Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C40B 50/18: using a particular method of attachment to the solid support
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

Disclosed herein are embodiments of a solid support suitable for synthesizing nucleic acid sequences. The solid support may have a structure according to Formula I, where CPG is controlled pore glass, and m, n, x, y, R1 and R2 are as defined herein. Also disclosed are methods for making and using the solid support, kits including solid support, and a universal linker phosphoramidite suitable for use in the solid support.

## Claims

### Claim 1

A solid support according to Formula I
wherein:
CPG is controlled pore glass;
m is 2, 3, 4, 5 or 6;
x is 1, 2, 3, 4 or 5;
y is from 2 to 12;
n is 3, 4, 5, 6, 7, 8, 9 or 10;
each R1 independently is C1-6alkyl, —(CH2)1-6CN, —(CH2)1-6OR′ or a thermolytic phosphate protecting group;
R′ is aliphatic, aryl, or aralkyl;
R2 is H,
p is 2, 3, 4, 5, 6, 7, 8, 9 or 10;
R3 is H or
R4 is H or OR6;
R5 is PG or a nucleic acid sequence;
R6 is pixyl, TBDMS, TBDPS, TMS, TES, or TIPS.
T is 1, 2, 3, or 4;
BP is a nucleic acid base where an exocyclic amine, if present, is protected; and
PG is a protecting group.

### Claim 2 (depends on 1)

The solid support of claim 1, wherein:
PG is 4,4′-dimethoxytrityl (DMTr);
m is 2, 3 or 4;
x is 1, 2 or 3;
y is from 3 to 10;
n is from 3 to 7; or
a combination thereof.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The solid support of claim 1, wherein the solid support has a formula selected from Formula II, Formula III, Formula IV, Formula V, Formula VII, Formula XI or Formula XIII:

### Claim at position 5

5-9. (canceled)

### Claim 10 (depends on 1)

The solid support of claim 1, wherein n is 5.

### Claim 11 (depends on 1)

The solid support of claim 1, wherein m, x, y and n are selected to produce a support backbone length from the silicon atom to the R2 moiety of from 50 atoms to 400 atoms.

### Claim 12 (depends on 11)

The solid support of claim 11, wherein the support backbone length is from 100 atoms to 150 atoms.

### Claim 13 (depends on 1)

The solid support of claim 1, wherein the thermolabile phosphate protecting group has a structure
wherein:
X is O or S;
R7 is H, Ra, ORa, SRa, or N(Rb)2;
Ra is Rd;
Rb is H, Rd or two Rbs together with the nitrogen to which they are attached, form a 3- to 7-membered heterocyclyl;
Z is O, S, N(Rc), C(Rc)2 or C(Rc)2C(Rc)2;
each Rc independently is H or Rd, or one Rd in combination with the C═X moiety and one Ra or Rb from R7 together form a 3- to 7-membered cycloaliphatic or heterocyclyl ring;
Rd is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or aralkyl;
each R8 independently is H or Rd, or one R8 together with Z forms an aryl ring;
each R9 independently is H or Rd, or one R9 and one R8 together with the atoms to which they are attached, forms a moiety having a formula
wherein r is 0 to 6; and
each R10 independently is H, C1-6alkyl, NO2, —N(C1-6alkyl)2, —OC1-6alkyl, —SC1-6alkyl, —CN, or halogen, provided that the aromatic ring substituted with R10 is one carbon removed from the phosphate oxygen of Formula I.

### Claim 14 (depends on 1)

The solid support of claim 1, wherein the thermolabile phosphate protecting group is selected from:

### Claim 15 (depends on 1)

The solid support of claim 1, wherein each R1 independently is C1-4alkyl or —(CH2)1-4CN.

### Claim 16 (depends on 15)

The solid support of claim 15, wherein each R1 is —CH2CH2CN.

### Claim 17 (depends on 1)

The solid support of claim 1, wherein R2 is H.

### Claim 18 (depends on 1)

The solid support of claim 1, wherein R2 is

### Claim 19 (depends on 1)

The solid support of claim 1, wherein R2 is

### Claim 20 (depends on 19)

The solid support of claim 19, wherein p is 6.

### Claim 21 (depends on 19)

The solid support of claim 19, wherein R3 is H.

### Claim 22 (depends on 19)

The solid support of claim 19, wherein R3 is

### Claim 23 (depends on 22)

The solid support of claim 22, wherein BP is exocyclic amine-protected adenine, exocyclic amine-protected cytosine, exocyclic amine-protected guanine, thymine, uracil, hypoxanthine, xanthine, exocyclic amine-protected 7-methylguanine, 5,6-dihydrouracil, exocyclic amine-protected 5-methylcytosine, or exocyclic amine-protected 5-hydroxymethylcytosine.

### Claim 24 (depends on 22)

The solid support of claim 22, wherein R4 is H.

### Claim 25

(canceled)

### Claim 26 (depends on 22)

The solid support of claim 22, wherein R4 is OR6.

### Claim 27 (depends on 22)

The solid support of claim 22, wherein:
R4 is H and BP is exocyclic amine-protected adenine, exocyclic amine-protected cytosine, exocyclic amine-protected guanine, or thymine; or
R4 is OR6 and BP is exocyclic amine-protected adenine, exocyclic amine-protected cytosine, exocyclic amine-protected guanine, or uracil.

### Claim 28 (depends on 19)

The solid support of claim 19, wherein:
BP is adenine, cytosine, or guanine, where the exocyclic amine is protected by a benzoyl (Bz), isobutyryl(iBu), phenoxyacetyl (Pac), phenylsulfonylethoxycarbonyl, p-nitrophenyloxycarbonyl, allyloxycarbonyl, or levulinyl group; or
BP is thymine or uracil.

### Claim at position 25

29-31. (canceled)

### Claim 32 (depends on 1)

The solid support of claim 1, wherein:
R6 is TBDMS;
t is 2;
R5 is PG; or
a combination thereof.

### Claim at position 27

33-34. (canceled)

### Claim 35 (depends on 1)

The solid support of claim 1, wherein R5 is a nucleic acid sequence.

### Claim 36 (depends on 35)

The solid support of claim 35, wherein:
the nucleic acid sequence comprises one or more DNA sequences; or
the nucleic acid sequence comprises one or more RNA sequences.

### Claim 37 (depends on 36)

The solid support of claim 36, wherein:
the one or more DNA sequences comprise one or more antisense DNA sequences; or
the one or more RNA sequences comprise one or more antisense RNA sequences, one or more microRNA (miRNA) sequences, one or more small interfering RNA (siRNA) sequences, one or more repeat-associated small interfering RNA (rasiRNA) sequences, or combinations thereof.

### Claim at position 31

38-39. (canceled)

### Claim 40 (depends on 1)

The solid support of claim 1, selected from:
wherein BP is an exocyclic amine-protected adenine, an exocyclic amine-protected cytosine, an exocyclic amine-protected guanine, thymine or uracil.

### Claim 41 (depends on 1)

The solid support of claim 1, wherein BP comprises a protecting group selected from benzoyl, isobutyryl, or phenoxyacetyl.

### Claim 42 (depends on 41)

The solid support of claim 41, wherein BP is selected from N6-benzoyl adenine (ABz), N4-benzoyl cytosine (CBz), N2-isobutyryl guanine (GiBu), thymine (T), N6-phenoxyacetyl adenine (APac), N4-phenoxyacetyl cytosine (CPac), N2-phenoxyacetyl guanine (GPac), or uracil (U).

### Claim 43 (depends on 1)

The solid support of claim 1, wherein a loading of the support on the CPG is from 5 μmol/g to 50 μmol/g.

### Claim 44 (depends on 1)

A method for synthesizing a nucleic acid sequence, comprising:
loading a solid support according to claim 1 into a DNA/RNA synthesizer; and
operating the synthesizer to produce a desired nucleic acid sequence.

### Claim 45 (depends on 32, 44)

The method of claim 44, wherein the solid support is a solid support according to claim 32 where R5 is PG.

### Claim 46 (depends on 45)

The method of claim 45, wherein R5 is DMTr.

### Claim 47

(canceled)

### Claim 48 (depends on 1)

A kit, comprising the solid support of claim 1.

### Claim 49

(canceled)

### Claim 50 (depends on 40, 48)

The kit of claim 48, wherein the kit comprises a solid support of claim 40.

### Claim 51 (depends on 50)

The kit of claim 50, wherein the kit comprises a solid support selected from:

### Claim 52 (depends on 48)

The kit of claim 48, wherein the kit comprises a solid support selected from:
wherein BP is an exocyclic amine-protected adenine, an exocyclic amine-protected cytosine, an exocyclic amine-protected guanine, thymine or uracil.

### Claim 53 (depends on 48)

The kit of claim 48, further comprising a protected 2′-deoxynucleoside, ribonucleoside, and/or chemically modified nucleoside wherein an exocyclic amine on the deoxynucleoside, ribonucleoside or chemically modified nucleoside, if present, also is protected.

### Claim 54 (depends on 53)

The kit of claim 53, wherein the 2′-deoxynucleoside is DMTrdABz, DMTrdCBz, DMTrdGiBu, or DMTrT), or the ribonucleosides is DMTrAPac-2′-OTBDMS, DMTrCPac-2′-OTBDMS, DMTrGPac-2′-OTBDMS, or DMTrU-2′-OTBDMS.
